Novartis: Autoimmune Diseases trials

The registry lists 11 Autoimmune Diseases studies with Novartis as lead sponsor. 3 are open to participants now and 7 have results posted.

Phase 1 1Phase 2 5Phase 3 4Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenRecruitingNCT07621809Phase 3
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.RecruitingNCT06858319Phase 3
• Secukinumab Open Label Roll-over Extension ProtocolRecruitingNCT04638647Phase 4
• A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's SyndromeTerminatedNCT04035668Phase 2Results posted
• Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's SyndromeCompletedNCT03905525Phase 2Results posted
• Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary SarcoidosisCompletedNCT02888080Phase 2Results posted
• Efficacy and Safety of Ofatumumab in Treatment of Pemphigus VulgarisTerminatedNCT01920477Phase 3Results posted
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple SclerosisTerminatedNCT01874340Phase 2Results posted
• Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type PsoriasisCompletedNCT00770965Phase 2Results posted
• Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With MycophenolateCompletedNCT00351377Phase 3Results posted
• Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)TerminatedNCT05203419Phase 1